ÂÜÀòÂÒÂ×

Dr. Chen received training in both hematology (M.D.) and immunology (Ph.D.) followed by over twenty years of clinical research and development experience, including over ten years of biopharmaceutical industry experience and five years as a practicing hematologist. During her time in the industry, she has led global, cross-functional teams in the design and execution of first-in-human clinical trials as well as trials in Phase 1 through Phase 3 in patients with AML, multiple myeloma, and breast cancer. She has contributed to the preparation and submission of regulatory documents and attended regulatory meetings to support Investigational New Drug (IND) and NDA applications in the US, EU, and other regions. Over the course of her career, she has authored over 50 peer-reviewed publications in high-impact journals. Dr. Chen joins Actinium from GlycoMimetics, Inc., where she led multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301), which is enrolling 380 patients with R/R AML at approximately 50 centers across nine countries. In this effort, Dr. Chen managed relationships with study investigators, created necessary protocols, Investigational Brochures, and target product profiles. Previously, Dr. Chen held the position of Medical Director, Global Clinical Lead–Clinical Science at Takeda Pharmaceuticals International where she developed clinical trials and protocols for T-cell and B-cell targeting therapies for oncology and inflammatory diseases. In this role, she successfully led multidisciplinary teams in the submission of an IND and Clinical Trial Application. Prior to Takeda, Dr. Chen worked at Pfizer (Wyeth), as Translational Medicine Team Lead-Translational Immunology. In this role, Dr. Chen supported biomarker development to support clinical development in hematology, oncology, and inflammatory diseases for biologics and small molecules. At Pfizer, she contributed to the scientific, clinical, and commercial development of the R&D pipeline and coordinated clinical development plans and protocols.